Thomas M Habermann

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint New developments in the management of diffuse large B-cell lymphoma
    Thomas M Habermann
    Mayo Clinic, Rochester, MN 55905, USA
    Hematology 17:S93-7. 2012
  2. doi request reprint Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
    Thomas M Habermann
    Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 145:344-9. 2009
  3. ncbi request reprint Splenectomy, interferon, and treatments of historical interest in hairy cell leukemia
    Thomas M Habermann
    Department of Hematology, Mayo Clinic College of Medicine, 200 First Street, SW Rochester, MN 55905, USA
    Hematol Oncol Clin North Am 20:1075-86. 2006
  4. ncbi request reprint Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    Thomas M Habermann
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 24:3121-7. 2006
  5. doi request reprint Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses
    Thomas M Habermann
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 52:18-20. 2011
  6. pmc Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma
    James R Cerhan
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 17:3161-9. 2008
  7. pmc Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 87:865-9. 2012
  8. pmc Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma
    Matthew J Maurer
    Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 29:1620-6. 2011
  9. ncbi request reprint Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas
    Deepti Behl
    Division of Hematology Department Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 137:409-15. 2007
  10. ncbi request reprint A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma
    Ivana N M Micallef
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 107:2826-32. 2006

Research Grants

  1. EASTERN COOPERATIVE ONCOLOGY GROUP
    Thomas Habermann; Fiscal Year: 2007

Detail Information

Publications96

  1. doi request reprint New developments in the management of diffuse large B-cell lymphoma
    Thomas M Habermann
    Mayo Clinic, Rochester, MN 55905, USA
    Hematology 17:S93-7. 2012
    ..This review will describe the contribution of immunochemotherapy and other interventions in diffuse large B-cell lymphoma evaluating past clinical trials, review early clinical trial observations, and discuss current future directions...
  2. doi request reprint Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
    Thomas M Habermann
    Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 145:344-9. 2009
    ..In conclusion, oral lenalidomide monotherapy is well tolerated and active in relapsed or refractory MCL...
  3. ncbi request reprint Splenectomy, interferon, and treatments of historical interest in hairy cell leukemia
    Thomas M Habermann
    Department of Hematology, Mayo Clinic College of Medicine, 200 First Street, SW Rochester, MN 55905, USA
    Hematol Oncol Clin North Am 20:1075-86. 2006
    ....
  4. ncbi request reprint Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    Thomas M Habermann
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 24:3121-7. 2006
    ....
  5. doi request reprint Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses
    Thomas M Habermann
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 52:18-20. 2011
    ..This review summarizes treatment approaches utilized before the adenosine deaminase inhibitors. These historic approaches may still be utilized in patients with relapsed or refractory disease...
  6. pmc Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma
    James R Cerhan
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 17:3161-9. 2008
    ....
  7. pmc Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 87:865-9. 2012
    ..99, P = 0.009, overall survival-HR 1.93, P = 0.021). Elevated pretreatment serum IP-10 levels are therefore associated with an increased likelihood of disease relapse and an inferior survival in patients with DLBCL...
  8. pmc Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma
    Matthew J Maurer
    Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 29:1620-6. 2011
    ..This assay has prognostic value in plasma cell proliferative disorders. There are limited data on serum FLC in B-cell malignancies...
  9. ncbi request reprint Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas
    Deepti Behl
    Division of Hematology Department Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 137:409-15. 2007
    ..89 x 10(9)/l (5/39, 13%) (P < 0.0001). Multivariate analysis showed ALC to be an independent predictor for TTP. This study supports our hypothesis that a higher ALC predicts longer TTP following rituximab therapy...
  10. ncbi request reprint A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma
    Ivana N M Micallef
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 107:2826-32. 2006
    ....
  11. pmc Risk of non-Hodgkin lymphoma in association with germline variation in complement genes
    James R Cerhan
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 145:614-23. 2009
    ..015; OR = 0.68; 95% 0.56-0.84) remained noteworthy. Associations were similar for the common NHL subtypes. In summary, we provide evidence for a role of genetic variation in complement genes, particularly C5 and C9, and NHL risk...
  12. pmc The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender
    Jennifer L Kelly
    School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA
    Ann Epidemiol 22:855-62. 2012
    ..To evaluate the association of body mass index (BMI) and physical activity (PA) during adulthood and at the age of 18 years with risk of non-Hodgkin lymphoma (NHL)...
  13. doi request reprint Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma
    Luis F Porrata
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 157:321-30. 2012
    ..ALC/AMC-DX is a low cost, already standarized, biomarker to predict clinical outcomes in NLPHL...
  14. doi request reprint Association of resident fatigue and distress with perceived medical errors
    Colin P West
    Division of General Internal Medicine, Department of Medicine, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    JAMA 302:1294-300. 2009
    ..Fatigue and distress have been separately shown to be associated with medical errors. The contribution of each factor when assessed simultaneously is unknown...
  15. doi request reprint A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
    Patrick B Johnston
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Hematol 85:320-4. 2010
    ..Four patients experienced a Grade 3 or higher pulmonary toxicity. Everolimus has single-agent activity in relapsed/refractory HL and provides proof-of-concept that targeting the mTOR pathway in HL is clinically relevant...
  16. pmc Trans fatty acid intake is associated with increased risk and n3 fatty acid intake with reduced risk of non-hodgkin lymphoma
    Bridget Charbonneau
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
    J Nutr 143:672-81. 2013
    ..In conclusion, diets high in TFAs, processed meats, and higher fat dairy products were positively associated with NHL risk, whereas diets high in n3 fatty acids and total seafood were inversely associated with risk...
  17. pmc Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era
    Thomas M Habermann
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 112:2694-702. 2008
    ..These data support a role for germ line variation in immune genes, particularly genes associated with a proinflammatory state, as predictors of late survival in DLBCL...
  18. pmc Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study
    Susan M Geyer
    Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 116:2993-3000. 2010
    ..Smoking, alcohol use, and obesity appear to increase the risk of developing non-Hodgkin lymphoma (NHL), but to the authors' knowledge, few studies to date have assessed their impact on NHL prognosis...
  19. doi request reprint Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma
    Luis F Porrata
    Division of Hematology Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Hematol 84:93-7. 2009
    ..ALC-R was an independent prognostic factor for OS [RR = 0.4, P < 0.01] and PFS [RR = 0.5, P < 0.005]. ALC-R predicts survival suggesting that host immunity is an important variable predicting survival in first relapsed DLBCL...
  20. pmc A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 region
    James R Cerhan
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Epidemiol Biomarkers Prev 21:1799-806. 2012
    ..Non-Hodgkin lymphoma (NHL) is a malignancy of lymphocytes, and there is growing evidence for a role of germline genetic variation in immune genes in NHL etiology...
  21. pmc Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas
    Thomas E Witzig
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA
    Blood 118:4882-9. 2011
    ..In view of its excellent toxicity profile and novel mechanism of action, further studies in combination with other agents appear warranted. This trial is registered at www.clinicaltrials.gov as #NCT00082888...
  22. pmc Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma
    Bridget Charbonneau
    Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 87:880-5. 2012
    ..1, along with C9, were associated with FL EFS after adjusting for clinical variables, and if replicated, these findings add further support for the role of host innate immunity in FL prognosis...
  23. ncbi request reprint Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group
    Thomas E Witzig
    Department of Internal Medicine, Division of Hematology, Mayo Clinic 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:1103-8. 2005
    ..The goals of this study were to assess the overall response rate (ORR) to rituximab in this patient population and to determine the time-to-progression (TTP) and time-to-subsequent-chemotherapy (TTSC)...
  24. pmc Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma
    Carrie A Thompson
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 86:998-1000. 2011
    ..84; 95% CI: 1.84-12.7) and OS (HR = 8.87; 95% CI: 2.35-33.52) compared to patients with normal FLC. Further studies of FLC in HL are warranted...
  25. ncbi request reprint Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma
    William G Martin
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:7614-20. 2005
    ..We reviewed our experience with BPT in HL to better delineate outcome and appropriate treatment in these patients...
  26. pmc Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study
    Bridget Charbonneau
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Cytokine 60:882-9. 2012
    ..Abnormal immune function is a key factor in predisposition to non-Hodgkin lymphoma (NHL). We evaluated the association of 30 cytokines individually and as a profile with diffuse large B-cell (DLBCL) and follicular (FL) lymphomas...
  27. doi request reprint Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma
    Luis F Porrata
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leuk Lymphoma 53:2159-65. 2012
    ..The AMC/ALC score was able to further stratify DLBCL clinical outcomes by COO. The AMC/ALC score was independent of COO and added to its ability to identify patients with high-risk disease...
  28. pmc Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma
    Luis F Porrata
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Haematologica 97:262-9. 2012
    ..We, therefore, studied whether the peripheral blood absolute lymphocyte count/absolute monocyte count ratio at diagnosis affects survival in classical Hodgkin's lymphoma...
  29. pmc Food-frequency questionnaire-based estimates of total antioxidant capacity and risk of non-Hodgkin lymphoma
    Shernan G Holtan
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Int J Cancer 131:1158-68. 2012
    ....
  30. pmc If you feed them, they will come: a prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical center
    Colin M Segovis
    Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    BMC Med Educ 7:22. 2007
    ..The present study examined whether attendance at medical grand rounds increased after providing complimentary food to attendees and also assessed attendee attitudes about complimentary food...
  31. pmc Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma
    Matthew T Drake
    College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:4191-8. 2010
    ..Recent data also suggest that vitamin D insufficiency is related to inferior prognosis in some cancers, although there are no data for NHL...
  32. ncbi request reprint Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone
    Lijo Simpson
    Division of Hematology, Department of Medicine, Rochester, MN, USA
    Leuk Lymphoma 48:1332-7. 2007
    ..Patients with progressive disease on DHAP should be considered for alternative salvage regimens or experimental therapy...
  33. doi request reprint CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma
    Nadia N Laack
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Int J Radiat Oncol Biol Phys 81:476-82. 2011
    ....
  34. ncbi request reprint A prospective study of the relationship between medical knowledge and professionalism among internal medicine residents
    Colin P West
    Division of General Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55095, USA
    Acad Med 82:587-92. 2007
    ..To explore residents' competency in medical knowledge and in empathy, one element of professionalism, and to evaluate the relationship between competencies in these domains...
  35. pmc Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource
    Brian K Link
    Brian K Link, Sergei I Syrbu, University of Iowa College of Medicine, Iowa City, IA and Matthew J Maurer, Grzegorz S Nowakowski, Stephen M Ansell, William R Macon, Susan L Slager, Carrie A Thompson, David J Inwards, Patrick B Johnston, Joseph P Colgan, Thomas E Witzig, Thomas M Habermann, and James R Cerhan, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN
    J Clin Oncol 31:3272-8. 2013
    ..This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series begun after diffusion of rituximab use...
  36. ncbi request reprint The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma
    Ivana N M Micallef
    Divison of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Lymphoma 47:1794-9. 2006
    ..In conclusion, tIPI at the time of histological transformation is an important predictor of OS. A time to transformation > 4 years from diagnosis is associated with better OS...
  37. ncbi request reprint Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders
    Irene M Ghobrial
    Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, 200 First St, SW, Rochester, MN 55905, USA
    J Clin Oncol 23:7574-82. 2005
    ..The objective of this study was to determine prognostic factors for overall survival in patients with post-transplantation lymphoproliferative disorders (PTLDs)...
  38. pmc Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study
    Thomas M Habermann
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:795-8. 2009
    ..The use of potential agents of risk by the survivors and the lack of access to potentially beneficial modalities highlights the need for further study of CAM in this population...
  39. pmc Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era
    Grzegorz S Nowakowski
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:412-7. 2010
    ..The clinical impact of statin use on the outcome of lymphoma patients treated with a rituximab-containing regimen is unknown...
  40. pmc The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation
    Clive S Zent
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 116:2201-7. 2010
    ..The aim of this study was to learn if inhibition of the mammalian target of rapamycin (mTOR) would produce tumor responses...
  41. pmc Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma
    Jennifer L Kelly
    School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA
    Cancer Epidemiol Biomarkers Prev 19:2847-58. 2010
    ..In addition, germline variation in both BCL2L11 (BIM) and CASP9, known regulators of apoptosis, has recently been linked to NHL risk. We conducted a comprehensive evaluation of 36 apoptosis pathway genes with risk of NHL...
  42. pmc Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
    Ivana N M Micallef
    Mayo Clinic Rochester, Rochester, MN, USA
    Blood 118:4053-61. 2011
    ..ER-CHOP is well tolerated and results appear promising as a combination therapy. This study was registered at www.clinicaltrials.gov as #NCT00301821...
  43. ncbi request reprint Absolute lymphocyte count predicts overall survival in follicular lymphomas
    Mustaqeem Siddiqui
    Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Br J Haematol 134:596-601. 2006
    ..677, P < 0.0001). These data suggest a critical role of FL patients' immune status at diagnosis on survival...
  44. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  45. ncbi request reprint Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia
    James R Cerhan
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Epidemiol Biomarkers Prev 11:1466-71. 2002
    ..For diffuse NHL, 64% of the cases were nodal, and there was no association of HRT with either nodal or extra-nodal sites. These data suggest that HRT is a risk factor for follicular NHL but not for diffuse or small lymphocyte NHL or CLL...
  46. ncbi request reprint Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma
    Stephen M Ansell
    Divisions of Hematology and Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 20:3885-90. 2002
    ..The goal of this analysis was to evaluate the therapy given to patients who relapsed after 90Y ibritumomab tiuxetan...
  47. ncbi request reprint Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma
    James R Cerhan
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Int J Cancer 106:784-8. 2003
    ..These data suggest that use of NSAIDs, either aspirin or other non-aspirin NSAIDs, are associated positively with risk of NHL, and that this association is independent of RA history...
  48. pmc Prognostic significance of pretreatment serum cytokines in classical hodgkin lymphoma
    Preethi Reddy Marri
    Authors Affiliations Divisions of Hematology and Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota and Department of Internal Medicine, College of Medicine, University of Iowa, Iowa City, Iowa
    Clin Cancer Res 19:6812-9. 2013
    ..As cytokines are critically involved in driving cHL, we tested whether pretreatment serum cytokine levels could provide additional prognostic information...
  49. pmc CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis
    Bridget Charbonneau
    Department of Health Sciences Research, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
    Cancer Immunol Immunother 62:1475-84. 2013
    ..64; 95% CI 0.47-0.87; p = 0.004). These results provide additional evidence for a role of host genetic variation in CXCR5 in lymphomagenesis, particularly for FL...
  50. pmc The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma
    Kathleen J Yost
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 54:290-7. 2013
    ..Overall, the FACT-G was a valid measure for monitoring QoL over time in patients with NHL. However, sensitivity analyses based on subscale scoring that excludes potentially problematic items may be warranted...
  51. pmc LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era
    James R Cerhan
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Leuk Lymphoma 53:1105-12. 2012
    ..In conclusion, germline genetic variation in LMO2 was associated with DLBCL prognosis and provided slightly stronger predictive ability relative to LMO2 IHC status...
  52. ncbi request reprint Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era
    Irene M Ghobrial
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Leuk Lymphoma 46:191-6. 2005
    ..004) and rituximab therapy (P = 0.03) were significant. Low IPI and rituximab therapy led to an improved overall survival in patients with CD20-positive PTLD...
  53. ncbi request reprint Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab
    Thomas E Witzig
    Department of Internal Medicine, Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:692-9. 2007
    ..To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab...
  54. pmc Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
    Stephen M Ansell
    Division of Hematology and Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Cancer Res 15:6446-53. 2009
    ..Blocking anti-CTLA-4 monoclonal antibodies improves host resistance to immunogenic tumors, and the anti-CTLA-4 antibody ipilimumab (MDX-010) has clinical activity against melanoma, prostate, and ovarian cancers...
  55. pmc Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma
    James R Cerhan
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 110:4455-63. 2007
    ....
  56. ncbi request reprint Therapeutic options in patients with lymphoma and severe liver dysfunction
    Irene M Ghobrial
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 79:169-75. 2004
    ....
  57. pmc Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma
    Jennifer L Kelly
    School of Medicine and Dentistry, University of Rochester, NY, USA
    Cancer Causes Control 23:1017-29. 2012
    ....
  58. ncbi request reprint Images and reflections from Mayo Clinic heritage
    Thomas M Habermann
    Mayo Graduate School of Medicine and Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:1324. 2003
  59. pmc Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkin's lymphoma: the Iowa Women's Health Study
    Carrie A Thompson
    Department of Medicine, College of Medicine Mayo Clinic, Rochester, MN, USA
    Int J Cancer 126:992-1003. 2010
    ..In conclusion, these results support a role for vegetables, and perhaps fruits and associated antioxidants from food sources, as protective factors against the development of NHL and follicular lymphoma in particular...
  60. ncbi request reprint Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?
    Irene M Ghobrial
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA
    Transplantation 79:244-7. 2005
    ....
  61. doi request reprint Splenectomy for massive splenomegaly: long-term results and risks for mortality
    Timucin Taner
    Department of Surgery Division of Hematology, Department of Internal Medicine Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN
    Ann Surg 258:1034-9. 2013
    ..To evaluate long-term outcomes after splenectomy for massive splenomegaly in a series of 222 consecutive patients...
  62. ncbi request reprint Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia
    Kami Maddocks-Christianson
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 139:398-404. 2007
    ..Physicians should strictly adhere to established criteria to initiate treatment for CLL patients who are not participating in clinical trials...
  63. pmc Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival
    James R Cerhan
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 109:5439-46. 2007
    ..Common variation in host immune genes warrants further evaluation as a promising class of prognostic factors in follicular lymphoma...
  64. ncbi request reprint Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior
    Rebecca F McClure
    Department of Laboratory Medicine and Pathology, Divisions of Anatomic Pathology and Hematopathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 29:1652-60. 2005
    ....
  65. ncbi request reprint Images and reflections from Mayo Clinic Heritage. Henry S. Plummer
    Thomas M Habermann
    Mayo Graduate School of Medicine and Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:1182. 2002
  66. ncbi request reprint Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome
    Anne J Novak
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:2247-53. 2004
    ..In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma...
  67. doi request reprint Endobronchial ultrasound and lymphoproliferative disorders: a retrospective study
    Seher Iqbal
    Division of Pulmonary and Critical Care Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Thorac Surg 94:1830-4. 2012
    ..The utility of EBUS-TBNA for the diagnosis of lymphoproliferative disorders involving the mediastinum or hila, or both, is unclear...
  68. doi request reprint The clinical spectrum of Castleman's disease
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 87:997-1002. 2012
    ..We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study...
  69. ncbi request reprint Clinical characteristics of familial vs. sporadic non-Hodgkin lymphoma in patients diagnosed at the Mayo Clinic (1986-2000)
    Celine M Vachon
    Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Lymphoma 45:929-35. 2004
    ..none (50%) (P = 0.20). We found little evidence of large differences between familial and sporadic NHL with regard to age, gender, site or histologic subtype...
  70. ncbi request reprint Association of perceived medical errors with resident distress and empathy: a prospective longitudinal study
    Colin P West
    Division of General Internal Medicine, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    JAMA 296:1071-8. 2006
    ..Medical errors are associated with feelings of distress in physicians, but little is known about the magnitude and direction of these associations...
  71. ncbi request reprint Natural killer/T-cell lymphoma with ocular and adnexal involvement
    John J Woog
    Mayo Clinic, Rochester, Minnesota, USA
    Ophthalmology 113:140-7. 2006
    ....
  72. ncbi request reprint Epstein-Barr virus infection as a complication of transplantation of a nerve allograft from a living related donor. Case report
    Mikko Larsen
    Department of Orthopedic Surgery, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Neurosurg 106:924-8. 2007
    ..Future studies are needed to quantify and minimize this complication. Nevertheless, it should be weighed against the potential functional benefit from using nerve allografts...
  73. ncbi request reprint Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study
    James R Cerhan
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Am J Epidemiol 156:527-35. 2002
    ..The opposite associations of body mass index with small lymphocytic lymphoma versus B-CLL may be a chance finding but, if confirmed, would suggest different etiologies for these malignancies...
  74. ncbi request reprint Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa women's health study (United States)
    James R Cerhan
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Causes Control 13:131-6. 2002
    ..Endogenous sex hormones, particularly estrogens, modulate the immune system, and non-Hodgkin lymphoma (NHL) is a tumor that is related to immunologic status...
  75. ncbi request reprint Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:67-74. 2002
    ..These data suggest that IL-12 and rituximab is an active combination and further studies of this combination in B-cell non-Hodgkin lymphoma are warranted...
  76. pmc Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma
    Thorvardur R Halfdanarson
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Gastroenterol Hepatol 8:1042-7. 2010
    ..We evaluated the temporal association between lymphoma and CD, along with clinical presentation, response to therapy, and prognosis...
  77. ncbi request reprint Posttransplant lymphoproliferative disorders
    Thomas M Habermann
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Cancer Treat Res 142:273-92. 2008
  78. ncbi request reprint Strategies for improving attendance at medical grand rounds at an academic medical center
    Paul S Mueller
    Division of General Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:549-53. 2003
    ..To evaluate, in this before-and-after study, the results of 5 strategies for improving attendance at medical grand rounds at a tertiary care academic medical center...
  79. ncbi request reprint Images and reflections from Mayo Clinic heritage
    Jan Stepanek
    Division of Preventive and Occupational Medicine and Internal Medicine, Mayo Graduate School of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 77:613. 2002
  80. ncbi request reprint Images and reflections from Mayo Clinic heritage
    Thomas M Habermann
    Mayo Graduate School of Medicine and the Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:964. 2002
  81. ncbi request reprint Current status of medical grand rounds in departments of medicine at US medical schools
    Paul S Mueller
    Division of General Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:313-21. 2006
    ..To assess the status of medical grand rounds (MGR) as an educational endeavor...
  82. ncbi request reprint Diffuse large B-cell lymphoma
    Thomas M Habermann
    Mayo Clinic, Rochester, Minn, USA
    Clin Adv Hematol Oncol 3:suppl 4-5. 2005
  83. ncbi request reprint Prospective study of survival outcomes in Non-Hodgkin's lymphoma patients with rheumatoid arthritis
    Ted R Mikuls
    Department of Medicine, University of Nebraska Medical Center, Omaha, NE 68198 3025, USA
    J Clin Oncol 24:1597-602. 2006
    ..In this prospective study, we examined the association of RA with survival in patients with NHL...
  84. ncbi request reprint The well-being of physicians
    Tait D Shanafelt
    Mayo Clinic, Rochester, Minnesota, USA
    Am J Med 114:513-9. 2003
  85. ncbi request reprint Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine
    Saskia A Bouwhuis
    Department of Dermatology and the Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Int J Dermatol 41:352-6. 2002
    ..Adverse effects include neutropenia, lymphocytopenia, and infectious complications. Our objective was to evaluate the efficacy of 2-CdA (2-6 seven-day cycles) in the treatment of late-stage, recalcitrant Sézary syndrome...
  86. ncbi request reprint Images and reflections from Mayo Clinic heritage
    Thomas M Habermann
    Mayo Graduate School of Medicine and the Division of Hematology and Internal Medicine, Mayo Foundation Education, Rochester, Minn, USA
    Mayo Clin Proc 77:188. 2002
  87. doi request reprint Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia
    Aisha Shaikh
    Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, MN, USA
    Clin Exp Nephrol 12:292-5. 2008
    ..As this case illustrates, the rituximab-induced cryoglobulin is not always benign. Pre- and post-treatment monitoring of the cryoglobulin level is advised in these patients...
  88. doi request reprint Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
    Peter H Wiernik
    Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY, USA
    J Clin Oncol 26:4952-7. 2008
    ..We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL...
  89. pmc Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
    Jane N Winter
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Blood 107:4207-13. 2006
    ..Our finding that Bcl-6(+) cases did not benefit from the addition of R to CHOP requires independent confirmation...
  90. ncbi request reprint Images and reflections from Mayo Clinic heritage
    Thomas M Habermann
    Mayo Clin Proc 78:672. 2003
  91. ncbi request reprint Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484
    Sandra J Horning
    Stanford University, 875 Blake Wilbur Dr, Suite 2338, Stanford, CA 94305 5821, USA
    J Clin Oncol 22:3032-8. 2004
    ....
  92. ncbi request reprint Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil
    Steven Vernino
    Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9036, USA
    Neurology 65:639-41. 2005
    ..Primary CNS lymphoma regressed on withdrawal of MM. Despite minimal short-term side effects and apparent efficacy, chronic treatment of MG with MM may be associated with increased risk of lymphoproliferative disorders...
  93. doi request reprint mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD)
    Shernan G Holtan
    Am J Hematol 83:688-9. 2008
  94. ncbi request reprint Involvement of the lacrimal drainage system by leukemia or lymphoma
    Chee Chew Yip
    Department of Ophthalmology, Tan Tock Seng Hospital, Singapore
    Ophthal Plast Reconstr Surg 18:242-6. 2002
    ..To determine the clinical characteristics and outcomes of patients with leukemic or lymphomatous involvement of the lacrimal drainage system (LDS)...
  95. ncbi request reprint NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes
    Friedrich Feuerhake
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1392-9. 2005
    ..In this large series of primary MLBCLs and DLBCLs, NFkappaB activation was not associated with amplification of the cREL locus, suggesting alternative pathogenetic mechanisms...
  96. ncbi request reprint Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
    Stefano Monti
    The Broad Institute, Cambridge, MA, USA
    Blood 105:1851-61. 2005
    ..These studies identify tumor microenvironment and host inflammatory response as defining features in DLBCL and suggest rational treatment targets in specific DLBCL subsets...

Research Grants3

  1. EASTERN COOPERATIVE ONCOLOGY GROUP
    Thomas Habermann; Fiscal Year: 2007
    ..These aims will be incorporated into a clinical trial infrastructure that is focused on institutional patient quality of care, clinical research associate (CRA) development, and faculty development. ..